VEGF Cancer Research Results

VEGF, Vascular endothelial growth factor: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
A signal protein produced by many cells that stimulates the formation of blood vessels. Vascular endothelial growth factor (VEGF) is a signal protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. This process is vital for normal physiological functions, such as wound healing and the menstrual cycle, but it is also a key factor in the growth and spread of tumors in cancer.
Because of its significant role in tumor growth and progression, VEGF has become a target for cancer therapies. Anti-VEGF therapies, such as monoclonal antibodies (e.g., bevacizumab) and small molecule inhibitors, aim to inhibit the action of VEGF, thereby reducing blood supply to tumors and limiting their growth. These therapies have been used in various types of cancer, including colorectal, lung, and breast cancer.
RCC, Renal cell Carcinoma: Click to Expand ⟱
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms.
The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42).
Scientific Papers found: Click to Expand⟱
5075- SSE,    Sodium selenite inhibits proliferation and metastasis through ROS‐mediated NF‐κB signaling in renal cell carcinoma
- vitro+vivo, RCC, 786-O
TumCP↓, TumCMig↓, Apoptosis↑, ROS↑, NF-kB↓, eff↓, E-cadherin↑, cl‑Casp3↑, VEGF↓, MMP9↓, EMT↓, MMP↓, mtDam↑, BAX↑, Bcl-2↓,
2125- TQ,    Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
- in-vitro, RCC, RCC4 - in-vitro, RCC, Caki-1
Hif1a↓, eff↝, uPAR↓, VEGF↓, CAIX↓, PDK1↓, GLUT1↓, LDHA↓, Glycolysis↓, e-lactateProd↓, i-ATP↓,
961- Z,    Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo
- in-vitro, RCC, RCC4 - vitro+vivo, GBM, U373MG - in-vitro, Nor, HUVECs
Hif1a↓, HIF-1↓, VEGF↓, TumCI↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

i-ATP↓, 1,   MMP↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

CAIX↓, 1,   Glycolysis↓, 1,   e-lactateProd↓, 1,   LDHA↓, 1,   PDK1↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   cl‑Casp3↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   MMP9↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   uPAR↓, 1,  

Angiogenesis & Vasculature ⓘ

HIF-1↓, 1,   Hif1a↓, 2,   VEGF↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   eff↝, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: VEGF, Vascular endothelial growth factor
1 Selenite (Sodium)
1 Thymoquinone
1 Zinc
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:24  Cells:%  prod#:%  Target#:334  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page